الفهرس 
Anemia in Haemodialysis PatientsOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Anemia and Resistance to to recombinant human erythropoietin (rhEPO) therapy are common common complications in Hemodialysis (HD) Patients . Here, we investigated how Hepcidin could influence anemia ,rhEPO resistance and the plasma levels of inflammatory markers which are interleukin 6 (IL6), high sensitivity c reactive protein (hsCRP). This study was conducted on 60 patients on maintenance hemodialysis presented to Ain Shams University Hospitals. They were 38 males & 22 females with mean age(48.83±13.89). Patients’ group was further divided into responders and non responders to treatment of rhEPO according to hemoglobin (Hb) level and erythropoietin resistance index (ERI). Also the studyincluded 40 healthy subjects of matched age and sex as a control group. They were 21 males and 19 females with mean ages (48.03±10.33). We measured hepcidin ,il6,hsCRP for all the subjects,and ERI was calculated for the patients group only.There was a statistically significant difference between patients’ and controlgroup were patients’ group had higher levels of hepcidin,IL6,hsCRP and lower Hb level. There was a statistically significant difference between responders and non responders patients’ group where the non responders group had higher levels of hepcidin,IL6,hsCRP andERI,and lower Hb levels. A positive correlation was found between hepcidin with IL6 and hsCRP,with a negative correlation with Hb level. Data demonstrated that hepcidin plays a major role in anemia of HD patients and it affects the levels of inflammatory markers and the degree of resistance to rhEPO treatment.